Veru Says Clinical Trial Of VERU-100 To Determine An Effective Dose Of VERU-100 For The Treatment Of Advanced Prostate Cancer Has Been Terminated As Endpoints Were Not Achieved At Current Dose Level
Portfolio Pulse from Benzinga Newsdesk
Veru has terminated the clinical trial of VERU-100 for the treatment of advanced prostate cancer as the endpoints were not achieved at the current dose level.
May 19, 2023 | 3:42 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Veru's stock price may be negatively impacted by the termination of the VERU-100 clinical trial for advanced prostate cancer due to unmet endpoints.
The termination of the VERU-100 clinical trial is a significant setback for Veru, as it indicates that the current dose level is not effective for treating advanced prostate cancer. This may lead to a decrease in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100